Efficacy and safety of TNF inhibitors in the treatment of juvenile idiopathic arthritis: a systematic literature review
Authors' conclusion
Tumor necrosis factor inhibitors are effective and well tolerated in the treatment of JIA
Study context
- Population
- Patients with juvenile idiopathic arthritis (JIA) in studies of TNFi with treatment arm ≥ 30 patients13 clinical trials
- Comparison
- TNFi in JIA
- Outcome
- Efficacy by JIA-ACR response criteria; safety by incidence of serious adverse events (SAEs) per 100 patient-years
Methodological detailsnarrative synthesis, Search cutoff March 16, 2021; 87 publications in qualitative synthesis, 19 describing 13 clinical trials
- Narrative synthesis
- Search cutoff March 16, 2021; 87 publications in qualitative synthesis, 19 describing 13 clinical trials
Main finding
As reported in the abstract
JIA-ACR30/50/70/90 response (% of patients, range across trials)
| Group | JIA-ACR30 (Week 12) | JIA-ACR50 (Week 12) | JIA-ACR70 (Week 12) | JIA-ACR90 (Week 12) | JIA-ACR30 (Week 16) | JIA-ACR50 (Week 16) | JIA-ACR70 (Week 16) | JIA-ACR90 (Week 16) | JIA-ACR30 (Week 14) | JIA-ACR50 (Week 14) | JIA-ACR70 (Week 14) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Adalimumab | 71-94% | 68-90% | 55-61% | 39-42% | |||||||
| Etanercept | 73-94% | 53-78% | 36-59% | 28% | |||||||
| Golimumab | 89% | 79% | 66% | 36% | |||||||
| Infliximab | 64% | 50% | 22% |
JIA-ACR30 (Week 12)
Adalimumab71-94%
Etanercept73-94%
Golimumab— not stated in the abstract
Infliximab— not stated in the abstract
JIA-ACR50 (Week 12)
Adalimumab68-90%
Etanercept53-78%
Golimumab— not stated in the abstract
Infliximab— not stated in the abstract
JIA-ACR70 (Week 12)
Adalimumab55-61%
Etanercept36-59%
Golimumab— not stated in the abstract
Infliximab— not stated in the abstract
JIA-ACR90 (Week 12)
Adalimumab39-42%
Etanercept28%
Golimumab— not stated in the abstract
Infliximab— not stated in the abstract
JIA-ACR30 (Week 16)
Adalimumab— not stated in the abstract
Etanercept— not stated in the abstract
Golimumab89%
Infliximab— not stated in the abstract
JIA-ACR50 (Week 16)
Adalimumab— not stated in the abstract
Etanercept— not stated in the abstract
Golimumab79%
Infliximab— not stated in the abstract
JIA-ACR70 (Week 16)
Adalimumab— not stated in the abstract
Etanercept— not stated in the abstract
Golimumab66%
Infliximab— not stated in the abstract
JIA-ACR90 (Week 16)
Adalimumab— not stated in the abstract
Etanercept— not stated in the abstract
Golimumab36%
Infliximab— not stated in the abstract
JIA-ACR30 (Week 14)
Adalimumab— not stated in the abstract
Etanercept— not stated in the abstract
Golimumab— not stated in the abstract
Infliximab64%
JIA-ACR50 (Week 14)
Adalimumab— not stated in the abstract
Etanercept— not stated in the abstract
Golimumab— not stated in the abstract
Infliximab50%
JIA-ACR70 (Week 14)
Adalimumab— not stated in the abstract
Etanercept— not stated in the abstract
Golimumab— not stated in the abstract
Infliximab22%
Safety
| Outcome | Adalimumab | Etanercept | Golimumab |
|---|---|---|---|
| SAE incidence across all time points (SAE/100PY, range) | 0-13.7 SAE/100PY | 0-20.0 SAE/100PY | 10.4-24.3 SAE/100PY |
- SAE incidence across all time points (SAE/100PY, range): golimumab: 1 study
SAE incidence across all time points (SAE/100PY, range)
- SAE incidence could not be estimated from the 2 infliximab publications
Original publication
Efficacy and safety of TNF inhibitors in the treatment of juvenile idiopathic arthritis: a systematic literature review. Pediatr Rheumatol Online J. Published 24 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →